PURPOSE: Glioblastoma (GBM) is a very aggressive and lethal brain tumor with poor prognosis. Despite new treatment strategies, patients' median survival is still lower than 1 year in most cases. The expression of the BUB gene family has demonstrated to be altered in a variety of solid tumors, pointing to a role as putative therapeutic target. The purpose of this study was to determine BUB1, BUB3, and BUBR1 gene expression profiles in glioblastoma and to analyze the effects of BUB1 and BUBR1 inhibition combined or not with Temozolomide and radiation in the pediatric SF188 GBM cell line. METHODS: For gene expression analysis, 8 cell lines and 18 tumor samples were used. The effect of BUB1 and BUBR1 inhibition was evaluated using siRNA. Apoptosis, cell proliferation, cell cycle kinetics, micronuclei formation, and clonogenic capacity were analyzed after BUB1 and BUBR1 inhibition. Additionally, combinatorial effects of gene inhibition and radiation or Temozolomide (TMZ) treatment were evaluated through proliferation and clonogenic capacity assays. RESULTS: We report the upregulation of BUB1 and BUBR1 expression and the downregulation of BUB3 in GBM samples and cell lines when compared to white matter samples (p < 0.05). Decreased cell proliferation and colony formation after BUB1 and BUBR1 inhibition were observed, along with increased micronuclei formation. Combinations with TMZ also caused cell cycle arrest and increased apoptosis. Moreover, our results demonstrate that BUB1 and BUBR1 inhibition sensitized SF188 cells to γ-irradiation as shown by decreased growth and abrogation of colony formation capacity. CONCLUSION: BUB1 and BUBR1 inhibition decreases proliferation and shows radiosensitizing effects on pediatric GBM cells, which could improve treatment strategies for this devastating tumor. Collectively, these findings highlight the potentials of BUB1 and BUBR1 as putative therapeutic targets for glioblastoma treatment.
PURPOSE:Glioblastoma (GBM) is a very aggressive and lethal brain tumor with poor prognosis. Despite new treatment strategies, patients' median survival is still lower than 1 year in most cases. The expression of the BUB gene family has demonstrated to be altered in a variety of solid tumors, pointing to a role as putative therapeutic target. The purpose of this study was to determine BUB1, BUB3, and BUBR1 gene expression profiles in glioblastoma and to analyze the effects of BUB1 and BUBR1 inhibition combined or not with Temozolomide and radiation in the pediatric SF188 GBM cell line. METHODS: For gene expression analysis, 8 cell lines and 18 tumor samples were used. The effect of BUB1 and BUBR1 inhibition was evaluated using siRNA. Apoptosis, cell proliferation, cell cycle kinetics, micronuclei formation, and clonogenic capacity were analyzed after BUB1 and BUBR1 inhibition. Additionally, combinatorial effects of gene inhibition and radiation or Temozolomide (TMZ) treatment were evaluated through proliferation and clonogenic capacity assays. RESULTS: We report the upregulation of BUB1 and BUBR1 expression and the downregulation of BUB3 in GBM samples and cell lines when compared to white matter samples (p < 0.05). Decreased cell proliferation and colony formation after BUB1 and BUBR1 inhibition were observed, along with increased micronuclei formation. Combinations with TMZ also caused cell cycle arrest and increased apoptosis. Moreover, our results demonstrate that BUB1 and BUBR1 inhibition sensitized SF188 cells to γ-irradiation as shown by decreased growth and abrogation of colony formation capacity. CONCLUSION:BUB1 and BUBR1 inhibition decreases proliferation and shows radiosensitizing effects on pediatric GBM cells, which could improve treatment strategies for this devastating tumor. Collectively, these findings highlight the potentials of BUB1 and BUBR1 as putative therapeutic targets for glioblastoma treatment.
Authors: Li Bie; Gang Zhao; Pui Cheng; Gaelle Rondeau; Steffen Porwollik; Yan Ju; Xiao-Qin Xia; Michael McClelland Journal: PLoS One Date: 2011-10-12 Impact factor: 3.240
Authors: Stefanie Galbán; Benjamin Lemasson; Terence M Williams; Fei Li; Kevin A Heist; Timothy D Johnson; Judith S Leopold; Thomas L Chenevert; Theodore S Lawrence; Alnawaz Rehemtulla; Tom Mikkelsen; Eric C Holland; Craig J Galbán; Brian D Ross Journal: PLoS One Date: 2012-04-20 Impact factor: 3.240
Authors: Jacob A Herman; Chad M Toledo; James M Olson; Jennifer G DeLuca; Patrick J Paddison Journal: Clin Cancer Res Date: 2014-08-07 Impact factor: 12.531
Authors: Ian M Cartwright; Cathy Su; Jeremy S Haskins; Victoria A Salinas; Shigeaki Sunada; Hao Yu; Mitsuru Uesaka; Hirokazu Hirakawa; David J Chen; Akira Fujimori; Takamitsu A Kato Journal: Int J Mol Sci Date: 2018-07-30 Impact factor: 5.923
Authors: Dennis S Metselaar; Aimée du Chatinier; Iris Stuiver; Gertjan J L Kaspers; Esther Hulleman Journal: Front Oncol Date: 2021-04-01 Impact factor: 6.244
Authors: Mirella Baroni; Caihong Yi; Saket Choudhary; Xiufen Lei; Adam Kosti; Denise Grieshober; Mitzli Velasco; Mei Qiao; Suzanne S Burns; Patricia R Araujo; Talia DeLambre; Mi Young Son; Michelina Plateroti; Marco A R Ferreira; Paul Hasty; Luiz O F Penalva Journal: Cancers (Basel) Date: 2021-03-24 Impact factor: 6.639